EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment

Aliki Ntzifa, Theodoros Marras, Galatea Kallergi, Athanasios Kotsakis, Vasilis Georgoulias, Evi Lianidou

Frontiers in Oncology · 21.10.2024 · 14

DOI: 10.3389/fonc.2024.1435537 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 21.10.2024. Verfasst von Aliki Ntzifa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Analysis of Circulating Tumor Cells Lab, Lab of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Athens…. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stavros Niarchos Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The heterogeneous and complex genetic landscape of NSCLC impacts the clinical outcomes of patients who will eventually develop resistance to osimertinib. Liquid biopsy (LB) analysis as a minimally invasive approach is a key step to efficiently identify resistance mechanisms and adjust to proper subsequent treatments. Materials and methods In the present study, we combined plasma-cfDNA and CTC analysis from 30 NSCLC patients in samples collected before treatment and at the progression of disease (PD). We detected molecular alterations at the DNA mutation ( EGFR, PIK3CA, KRAS G12C, BRAF V600E), DNA methylation ( RASSF1A, BRMS1, FOXA1, SLFN1, SHISA3, RARβ,, WIF-1, RASSF10 and APC ), gene expression ( CK-19, CK-18, CK-8, AXL, TWIST-1, PD-L1, PIM-1, Vimentin, ALDH-1 , and B2M ) and chromosomal level ( HER2 and MET amplification) as possible resistance mechanisms and druggable targets. We also studied the expression of PD-L1 in single CTCs using immunofluorescence.

Results

In some cases, T790M resistance EGFR mutation was detected at baseline in CTCs but not in the corresponding plasma cfDNA. PIK3CA mutations were detected only in plasma-cfDNA but not in corresponding CTCs. KRAS G12C and BRAF V600E mutations were not detected in the samples analyzed. MET amplification was detected in the CTCs of two patients before treatment whereas HER2 amplification was detected in the CTCs of three patients at baseline and in one patient at PD. DNA methylation analysis revealed low concordance between CTCs and cfDNA, indicating the complementary information obtained through parallel LB analysis. Results from gene expression analysis indicated high rates of vimentin-positive CTCs detected at all time points during osimertinib. Moreover, there was an increased number of NSCLC patients at PD harboring CTCs positive in PD-L1. AXL and PIM-1 expression detected in CTCs during treatment suggesting new possible therapeutic strategies.

Discussion

Our results reveal that comprehensive liquid biopsy analysis can efficiently represent the heterogeneous molecular landscape and provide prominent information on subsequent treatments for NSCLC patients at PD since druggable molecular alterations were detected in CTCs.

Schlagwörter

Stichwörter der Autor:innen

CTCNSCLCctDNAliquid biopsyosimertinibresistance

Autor:innen und Institutionen

  • Analysis of Circulating Tumor Cells Lab, Lab of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Athens, Greece.
  • Laboratory of Biochemistry/Metastatic Signaling, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, Patras, Greece.
  • Department of Medical Oncology, General University Hospital of Larissa, Larissa, Greece.
  • First Department of Medical Oncology, Metropolitan General Hospital of Athens, Cholargos, Greece.

Förderung

  • Stavros Niarchos Foundation

Zitieren

APA

Ntzifa, A., Marras, T., Kallergi, G., Kotsakis, A., Georgoulias, V., & Lianidou, E. (2024). Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1435537

Vancouver

Ntzifa A, Marras T, Kallergi G, Kotsakis A, Georgoulias V, Lianidou E. Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1435537

BibTeX
@article{Ntzifa2024,
  author = {Ntzifa, Aliki and Marras, Theodoros and Kallergi, Galatea and Kotsakis, Athanasios and Georgoulias, Vasilis and Lianidou, Evi},
  title = {Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment},
  journal = {Frontiers in Oncology},
  year = {2024},
  volume = {14},
  doi = {10.3389/fonc.2024.1435537}
}
Kostenlos starten →